ABBVIE INC (4AB.DE) Fundamental Analysis & Valuation

FRA:4AB • US00287Y1091

Current stock price

183.8 EUR
-9.4 (-4.87%)
Last:

This 4AB.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 4AB.DE Profitability Analysis

1.1 Basic Checks

  • 4AB had positive earnings in the past year.
  • 4AB had a positive operating cash flow in the past year.
  • 4AB had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 4AB had a positive operating cash flow.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

1.2 Ratios

  • 4AB's Return On Assets of 3.12% is fine compared to the rest of the industry. 4AB outperforms 75.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 14.42%, 4AB belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 11.34%.
  • The last Return On Invested Capital (14.42%) for 4AB is above the 3 year average (12.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.12%
ROE N/A
ROIC 14.42%
ROA(3y)3.28%
ROA(5y)5.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)12.12%
ROIC(5y)11.88%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

1.3 Margins

  • The Profit Margin of 4AB (6.84%) is better than 75.00% of its industry peers.
  • 4AB's Profit Margin has declined in the last couple of years.
  • 4AB has a Operating Margin of 34.23%. This is amongst the best in the industry. 4AB outperforms 90.00% of its industry peers.
  • 4AB's Operating Margin has improved in the last couple of years.
  • The Gross Margin of 4AB (71.62%) is comparable to the rest of the industry.
  • 4AB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 34.23%
PM (TTM) 6.84%
GM 71.62%
OM growth 3Y-0.41%
OM growth 5Y2.75%
PM growth 3Y-30.39%
PM growth 5Y-7.2%
GM growth 3Y0.04%
GM growth 5Y1.44%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 4AB.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
  • Compared to 1 year ago, 4AB has about the same amount of shares outstanding.
  • Compared to 5 years ago, 4AB has about the same amount of shares outstanding.
  • 4AB has a worse debt/assets ratio than last year.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 2.41 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • 4AB has a Altman-Z score of 2.41. This is in the better half of the industry: 4AB outperforms 65.00% of its industry peers.
  • The Debt to FCF ratio of 4AB is 3.79, which is a good value as it means it would take 4AB, 3.79 years of fcf income to pay off all of its debts.
  • 4AB has a Debt to FCF ratio of 3.79. This is amongst the best in the industry. 4AB outperforms 83.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.79
Altman-Z 2.41
ROIC/WACC1.81
WACC7.97%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 0.67 indicates that 4AB may have some problems paying its short term obligations.
  • 4AB's Current ratio of 0.67 is on the low side compared to the rest of the industry. 4AB is outperformed by 77.50% of its industry peers.
  • 4AB has a Quick Ratio of 0.67. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 4AB has a worse Quick ratio (0.56) than 78.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.56
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 4AB.DE Growth Analysis

3.1 Past

  • 4AB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.19%.
  • 4AB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.99% yearly.
  • Looking at the last year, 4AB shows a quite strong growth in Revenue. The Revenue has grown by 8.57% in the last year.
  • The Revenue has been growing slightly by 5.95% on average over the past years.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)8.57%
Revenue growth 3Y1.75%
Revenue growth 5Y5.95%
Sales Q2Q%10.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.08% on average over the next years. This is quite good.
  • Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 6.43% on average per year.
EPS Next Y48.4%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
EPS Next 5Y15.08%
Revenue Next Year10.06%
Revenue Next 2Y9.15%
Revenue Next 3Y8.57%
Revenue Next 5Y6.43%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

7

4. 4AB.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 21.20 indicates a rather expensive valuation of 4AB.
  • Compared to the rest of the industry, the Price/Earnings ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 81.25% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of 4AB to the average of the S&P500 Index (25.79), we can say 4AB is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 14.28, the valuation of 4AB can be described as correct.
  • 92.50% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, 4AB is valued a bit cheaper.
Industry RankSector Rank
PE 21.2
Fwd PE 14.28
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than 80.00% of the companies in the same industry.
  • 85.00% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.03
EV/EBITDA 15.6
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of 4AB may justify a higher PE ratio.
  • A more expensive valuation may be justified as 4AB's earnings are expected to grow with 22.01% in the coming years.
PEG (NY)0.44
PEG (5Y)N/A
EPS Next 2Y28.14%
EPS Next 3Y22.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. 4AB.DE Dividend Analysis

5.1 Amount

  • 4AB has a Yearly Dividend Yield of 3.07%.
  • 4AB's Dividend Yield is rather good when compared to the industry average which is at 0.60. 4AB pays more dividend than 97.50% of the companies in the same industry.
  • 4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
Industry RankSector Rank
Dividend Yield 3.07%

5.2 History

  • On average, the dividend of 4AB grows each year by 6.76%, which is quite nice.
Dividend Growth(5Y)6.76%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 4AB pays out 278.48% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP278.48%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

4AB.DE Fundamentals: All Metrics, Ratios and Statistics

ABBVIE INC

FRA:4AB (3/18/2026, 7:00:00 PM)

183.8

-9.4 (-4.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners76.17%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap324.99B
Revenue(TTM)61.16B
Net Income(TTM)4.19B
Analysts77.44
Price Target216.59 (17.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.07%
Yearly Dividend5.75
Dividend Growth(5Y)6.76%
DP278.48%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.46%
Min EPS beat(2)0.18%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.25%
Min EPS beat(4)0.18%
Max EPS beat(4)2.75%
EPS beat(8)8
Avg EPS beat(8)1.12%
EPS beat(12)10
Avg EPS beat(12)0.74%
EPS beat(16)12
Avg EPS beat(16)0.58%
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)-0.78%
Revenue beat(4)2
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)5
Avg Revenue beat(12)0.03%
Revenue beat(16)5
Avg Revenue beat(16)-0.64%
PT rev (1m)1.22%
PT rev (3m)1.57%
EPS NQ rev (1m)0.56%
EPS NQ rev (3m)-1.6%
EPS NY rev (1m)2.19%
EPS NY rev (3m)2.16%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)0.6%
Valuation
Industry RankSector Rank
PE 21.2
Fwd PE 14.28
P/S 6.13
P/FCF 21.03
P/OCF 19.69
P/B N/A
P/tB N/A
EV/EBITDA 15.6
EPS(TTM)8.67
EY4.72%
EPS(NY)12.87
Fwd EY7%
FCF(TTM)8.74
FCFY4.75%
OCF(TTM)9.33
OCFY5.08%
SpS30
BVpS-1.6
TBVpS-44.9
PEG (NY)0.44
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.12%
ROE N/A
ROCE 23.09%
ROIC 14.42%
ROICexc 15.28%
ROICexgc N/A
OM 34.23%
PM (TTM) 6.84%
GM 71.62%
FCFM 29.13%
ROA(3y)3.28%
ROA(5y)5.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)12.12%
ROIC(5y)11.88%
ROICexc(3y)13.19%
ROICexc(5y)12.96%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.1%
ROCE(5y)18.64%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.56%
OM growth 3Y-0.41%
OM growth 5Y2.75%
PM growth 3Y-30.39%
PM growth 5Y-7.2%
GM growth 3Y0.04%
GM growth 5Y1.44%
F-Score8
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.79
Debt/EBITDA 2.11
Cap/Depr 14.92%
Cap/Sales 1.98%
Interest Coverage 6.97
Cash Conversion 65.45%
Profit Quality 425.61%
Current Ratio 0.67
Quick Ratio 0.56
Altman-Z 2.41
F-Score8
WACC7.97%
ROIC/WACC1.81
Cap/Depr(3y)11.82%
Cap/Depr(5y)10.58%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.55%
Profit Quality(3y)434.7%
Profit Quality(5y)340.33%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y48.4%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
EPS Next 5Y15.08%
Revenue 1Y (TTM)8.57%
Revenue growth 3Y1.75%
Revenue growth 5Y5.95%
Sales Q2Q%10.04%
Revenue Next Year10.06%
Revenue Next 2Y9.15%
Revenue Next 3Y8.57%
Revenue Next 5Y6.43%
EBIT growth 1Y26.92%
EBIT growth 3Y1.33%
EBIT growth 5Y8.87%
EBIT Next Year42.07%
EBIT Next 3Y19.5%
EBIT Next 5Y10.21%
FCF growth 1Y-0.09%
FCF growth 3Y-9.76%
FCF growth 5Y1.19%
OCF growth 1Y1.19%
OCF growth 3Y-8.62%
OCF growth 5Y1.59%

ABBVIE INC / 4AB.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (4AB.DE). This can be considered as Undervalued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 4 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 278.48%.